Project Grant R43GM130187

The Alida Biosciences Inc. was awarded a $765,105 Project Grant from the National Institutes of Health National Human Genome Research Institute under the Human Genome Research federal grant program (CFDA 93.172) on August 17, 2021 to complete work by February 28, 2022. The grant funds the development of a new approach to analyze RNA modifications across entire transcriptomes in a multiplexed reaction at near single-base resolution. Currently available methods either lack sequence context or...

Federal Project Grant Award Summary Molecular Instruments, Inc. received a $306,788 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) with an award date of September 30, 2025, and a completion date of September 29, 2026. The award supports the development and advancement of probe technology for ultrasensitive RNA imaging utilizing Hybridization Chain Reaction (HCR) methodology. The project...

Federal Project Grant Award Summary Lamprogen, Inc. received a $1.7M Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) awarded August 1, 2025, with completion targeted for April 30, 2027. The company is developing advanced semiconducting polymer dots (PDots) with narrow absorption and emission bands to significantly expand fluorescence spectral multiplexing capabilities in tissue imaging. The...

This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $302,605.00 to Chimerna Therapeutics, Inc. to develop synthetic biology approaches for bio-orthogonal labeling of circular RNAs. The key objectives are to: 1) optimize a bacterial strain and expression conditions for high-efficiency amino functionalization of circular RNAs, and 2) produce a variety of...

Partillion Bioscience Corp. was awarded a $659,037 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop reagent products enabling high-throughput screening and selection of single cells based on secreted bio-products. Under the Biomedical Research and Research Training program (CFDA 93.859), Partillion plans to transition its lab-on-a-particle technology—highlighted as a 2020 SLAS Innovation Award winner—into the first reagent product...

Montana Molecular LLC received a $364,367 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) for a one-year project period beginning September 1, 2025. The award supports the development of fluorescent biosensor assays designed to measure signaling kinetics of G-protein coupled receptor (GPCR) ligands that activate G12/13 pathways. The primary deliverable involves creating a live-cell, fluorescent assay compatible with standard plate...

This Project Grant award of $1,249,099 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) supports the development of a new class of small, bright, tunable, and biocompatible near-infrared (NIR-II) fluorescent probes for deep tissue molecular imaging. The University of California, Irvine (UC Irvine) will create a palette of DNA-stabilized silver nanoclusters (AgN-DNA) that emit in the NIR-II tissue transparency window (1,000-1,700 nm). These new...

Grant Award Summary Spectral Therapeutics, Inc. received a $322,388 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) effective August 1, 2025, through July 31, 2026, to develop and validate an optical-encoded bead technology platform for large-scale molecular library generation. The project addresses a critical bottleneck in combinatorial drug discovery by creating stimulated emission-encoded beads that enable instantaneous decoding during...

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded University of California, Irvine a $1.89 million Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) effective September 1, 2025, through August 31, 2029. The research initiative focuses on developing molecular lanterns—ultra-small ribonucleic acid (RNA) tags that assemble split luciferases—to enable real-time visualization and tracking of multiple RNA transcripts...